Gene Editing

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Posted on June 14, 2022 by Editorial Staff

Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='facebook' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/facebook.svg'>

Share on Facebook

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Twitter' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Twitter.svg'>

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Follow' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Follow.png'>

<img alt='' src='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=90&d=identicon&r=g' srcset='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=180&d=identicon&r=g 2x' class='avatar avatar-90 photo' height='90' width='90' />

Editorial Staff